Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Banna, Giuseppe Luigi; Cantale, Ornella; Muthuramalingam, S.; Cave, Judith; Comins, Charles; Cortellini, Alessio; Addeo, Alfredo; Signori, Alessio; McKenzie, Hayley; Escriu, Carles; Barone, Gloria; Chan, Samuel; Hicks, Alexander; Bainbridge, H.; Pinato, David J.; Ottensmeier, Christian; Gomes, Fábio

doi:10.1016/j.intimp.2022.108985

Cited by 20 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SII has been previously analyzed as a prognostic tool in multiple pathologies such as advanced non-small cell lung cancer [ 18 ] and extrahepatic cholangiocarcinoma [ 19 ]. In relation to its usefulness as a diagnostic tool, its application is limited, having been documented in contexts such as subacute thyroiditis [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

The BIDIAP index: a clinical, analytical and ultrasonographic score for the diagnosis of acute appendicitis in children

et al. 2023

View full text Add to dashboard Cite

Background Pediatric acute appendicitis (PAA) continues to be a diagnostic challenge today. The diagnostic performance of classical indices is only moderate, especially in pediatric population. This study aimed to define a clinical, radiological and analytical index for the diagnosis of PAA. Materials and methods This prospective study included 151 patients divided into two groups: (1) 53 patients with non-surgical abdominal pain (NSAP) and (2) 98 patients with a confirmed PAA. Sociodemographic and clinical characteristics were compared between groups using the Mann–Whitney U test and the Fisher exact test. To identify the predictors of PAA, we performed a multivariable logistic regression using a forward stepwise analysis and we assigned multiples of integer values to the selected variables. The diagnostic performance of the index was assessed by calculating the area under the receiver operating characteristic curve. Intra-cohort calibration was assessed with the Hosmer–Lemeshow test. Results We developed the BIDIAP index (BIomarkers for the DIagnosis of Appendicitis in Pediatrics), which included three variables that independently predicted higher odds of PAA: appendiceal caliber (≥ 6.9 mm), systemic immune-inflammation index (≥ 890) and peritoneal irritation, which scored 4, 3 and 2 points, respectively. Mean (SD) score of the participants was 2.38 (2.06) in group 1 and 7.89 (1.50) in group 2. The area under the ROC was 0.97 (95% CI 0.95–0.99). The cut-off point was established at 4 points, resulting in a sensitivity of 98.98% and a specificity of 77.78%. Conclusions The BIDIAP index has an exceptional diagnostic performance in PAA. The importance of these results lies in its novelty and in the simplicity of the index. Although external validation will be necessary, initial results look promising.

show abstract

Section: Discussionmentioning

confidence: 99%

The BIDIAP index: a clinical, analytical and ultrasonographic score for the diagnosis of acute appendicitis in children

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Several peripheral blood inflammatory indexes (such as the NLR, SII, albumin ratio and LDH) have been investigated and confirmed as baseline prognostic indicators for patients with NSCLC receiving ICIs alone or in association with chemotherapy in retrospective and prospective studies. 9 Some of these have been grouped in prognostic models which include other clinical factors or different biomarkers such as the LIPI score (based on derived NLR and LDH), 30 Cortellini score (NLR and PD-L1), 31 LIPS-3 score (NLR, ECOG and steroids), 32 Gustave Roussy immune score (LDH, albumin and NLR), 33 and Royal Marsden Hospital Prognostic score (LDH, albumin and the number of metastatic sites). 34 Inflammation is an intrinsic part of most malignancies which affects the immune response by altering the tumor microenvironment and influencing neo-antigen presentation by T cells.…”

Section: Discussionmentioning

confidence: 99%

“…35,36 Interestingly, a positive association between SII and PFS emerged in the ICI-only exploratory subgroup confirming that the role of peripheral blood systemic inflammation indexes may be more implicated in ICI response and partially masked by the addition of the chemotherapy. 31 The persistence of inflammation may be one of the reasons for ICI failure because of the production of cytokines and alteration of oxidative stress and glycolytic metabolic pathways, which subsequently interfere with T cell activation. 37 This serves as a rationale for clinical trials combining ICIs with cytokine inhibitors such as IFN-α and IL-2.…”

Section: Discussionmentioning

confidence: 99%

Assessing the role of colonic and other anatomical sites uptake by [¹⁸F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundInflammation in non‐small cell lung cancer (NSCLC) may impair the response to immune checkpoint inhibitors (ICIs) and can be indicated by peripheral blood inflammatory indexes. 2‐deoxy‐2‐[18F]fluoro‐D‐glucose positron emission tomography/computed tomography ([18F] FDG‐PET/CT) may be used as a marker of inflammation by measuring glucose metabolism in different colonic sites.MethodsThis retrospective analysis aimed to investigate the correlation between [18F] FDGPET/CT SUVratio in six gastrointestinal districts, the spleen, the pharynx and the larynx alongside the most avid tumor lesion with peripheral blood inflammatory indexes, including the neutrophil‐to‐lymphocyte ratio (NLR), systemic immune‐inflammatory index (SII, i.e., NLR times platelets) and lactate dehydrogenase (LDH), in patients with [18F] FDG‐PET/CT staged IV NSCLC who received first‐line immune checkpoint inhibitors (ICIs). The role of SUVratios and peripheral blood inflammatory indexes in predicting overall survival (OS) and progression‐free survival (PFS) was then explored.ResultsA total of 43 patients were treated with first‐line ICI alone (58%) or in combination with chemotherapy (42%). A significant correlation was only found between the rectosigmoid SUVratio and NLR (p = 0.0465). NLR >5.5 and LDH > 333.5 were associated with a worse OS (p = 0.033 and p = 0.009, respectively). The SII was associated with a worse PFS in patients treated with ICI alone (p = 0.033). None of the SUVratios were significantly associated with OS or PFS, although a high left colon SUVratio showed a trend toward a worse PFS.ConclusionThere was no significant correlation between [18F]FDG PET/CT uptake in different anatomical sites, and in the tumor, and systemic immune‐inflammatory indexes. The prognostic role of high left colon SUVratio deserves further investigation.

show abstract

“…Blood samples were taken a week prior to stereotactic radiotherapy [31]. Banna et al showed that the number of metastatic sites ≥ 3 (p < 0.001 and p = 0.002), squamous histology (p = 0.033 and p = 0.013), and SII ≥ 1444 (p = 0.031 and p = 0.009, respectively) were associated with both worse OS and PFS [32]. However, none of the prognostic factors and inflammatory indices (NLR, PLR, SII, LMR) were statistically significant in terms of overall survival in both univariate and multivariate analysis [33].…”

Section: Figure 1 -Roc Curve Analysis For Optimal Cut-off Value Of In...mentioning

confidence: 99%

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Smorodska

Moskalenko

Kononenko

et al. 2022

EUMJ

View full text Add to dashboard Cite

Introduction. Prediction of lung cancer recurrence is one of the most urgent problems of modern oncology. Scientists are trying to find independent predictors that will help intensify, personalize the patient's treatment, and prevent the disease relapse on time. The study aimed to find indicators of inflammation that could be independent predictors of disease recurrence in patients with surgically resected non-small cell lung cancer. Materials and methods. The study was conducted retrospectively. The study group included 104 patients with non-small cell lung cancer who received surgical treatment and adjuvant chemotherapy or chemoradiotherapy from 2014 to 2018 at the Sumy Regional Clinical Oncology Dispensary. Based on the results of the blood count tests, the inflammation indices were calculated before chemotherapy or chemoradiotherapy and one month after their completion. Systemic inflammatory response index (SIRI), systemic inflammatory index (SII), neutrophil/lymphocyte ratio (NLR), platelets/lymphocytes ratio (PLR), lymphocyte/monocyte ratio (LMR), monocyte/lymphocyte ratio (MLR) were calculated. Using ROC analysis, cut-off points were found. Cox regression was used to find independent predictors of lung cancer recurrence. Results. During the observation period, relapse of the disease was recorded in 42 (40.4%) patients. The average recurrence-free survival was 56.3 months, range of 4–84.0 months (95% CI = 46.866–65.683). Before chemo- or chemoradiation therapy, the cut-off points for NLR1, PLR1, MLR1, LMR1, SII1, and SIRI1 were 1.80, 126.35, 0.22, 4.80, 521.22 and 0.96, respectively. Cut-off points for NLR2, PLR2, MLR2, LMR2, SII2, and SIRI2 at stage one month after completing courses of chemotherapy or chemoradiotherapy were 1.33, 153.80, 0.26, 3.98, 450.10 and 0.82 respectively. According to ROC analysis, only PLR1, SII1, LMR1, and LMR2 indices are reliable and can be used in further Cox regression analysis. Univariant Cox regression showed that LMR1 and SII1 were significantly associated with disease recurrence. Multivariate Cox regression identified SII1 as the only independent predictor of disease recurrence. Conclusions. Among numerous inflammation indices as an independent predictor for disease recurrence in non-small cell lung cancer patients who received surgical treatment and chemotherapy or chemoradiotherapy, only systemic inflammation index (SII1) at the stage before chemotherapy or chemoradiotherapy can be used. Indicators above 521.22 could be a predictor of high-risk recurrence of lung cancer.

show abstract

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Cited by 20 publications

References 46 publications

The BIDIAP index: a clinical, analytical and ultrasonographic score for the diagnosis of acute appendicitis in children

The BIDIAP index: a clinical, analytical and ultrasonographic score for the diagnosis of acute appendicitis in children

Assessing the role of colonic and other anatomical sites uptake by [¹⁸F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Cited by 20 publications

References 46 publications

The BIDIAP index: a clinical, analytical and ultrasonographic score for the diagnosis of acute appendicitis in children

The BIDIAP index: a clinical, analytical and ultrasonographic score for the diagnosis of acute appendicitis in children

Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About

Assessing the role of colonic and other anatomical sites uptake by [¹⁸F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors